In this project, we therefore aimed to evaluate epigenetic co-vulnerabilities of LSD1 in blast phase MPN with the goal to identify targetable dependencies that would increase the potency of LSD1 inhibitor treatment. The gene discussed is KDM1A; the disease is myeloproliferative neoplasm.